Table 2 Rectal adenocarcinomas: observed survival rates calculated by the actuarialmethod (95% confidence interval) by stage (TNM/UICC, 1997) [3] without distinctionof the R-status (R0, R1, R2, Rx) n = 641 cases
From: Rectal cancer in Luxembourg : a national population-based data report, 1988–1998
Stage I-IV | Stage I* | Stage II* | Stage III* | Stage IV* | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
n = 641 (100%) | n = 116 (18.1%) | n = 179 (27.9%) | n = 270 (42.1%) | n = 76 (11.9%) | ||||||
1 year | 78+/-3% | (n = 503) | 94+/-4% | (n = 109) | 88+/-5% | (n = 157) | 70+/-5% | (n = 188) | 64+/-11% | (n = 49) |
2 years | 64+/-4% | (n = 408) | 90+/-6% | (n = 104) | 77+/-6% | (n = 137) | 50+/-6% | (n = 135) | 42% ** | (n = 32) |
3 years | 54+/-4% | (n = 346) | 86+/-6% | (n = 100) | 65+/-7% | (n = 117) | 39+/-6% | (n = 106) | 30% ** | (n = 23) |
4 years | 49+/-4% | (n = 315) | 86+/-6% | (n = 100) | 58+/-7% | (n = 104) | 36+/-6% | (n = 97) | 18% ** | (n = 14) |
5 years | 46+/-4% | (n = 292) | 81+/-7% | (n = 94) | 55+/-7% | (n = 98) | 34+/-6% | (n = 92) | 11% ** | (n = 8) |